Evaluation of an intensive education program on the treatment of tobacco-use disorder for pharmacists: a study protocol for a randomized controlled trial

Maguy Saffouh El Hajj, Ahmed Awaisu, Nadir Kheir, Mohamad Haniki Nik Mohamed, Rula Shami Haddad, Rana Ahmed Saleh, Noora Mohammed Alhamad, Ahmad Mohd Almulla, Ziyad R Mahfoud, Maguy Saffouh El Hajj, Ahmed Awaisu, Nadir Kheir, Mohamad Haniki Nik Mohamed, Rula Shami Haddad, Rana Ahmed Saleh, Noora Mohammed Alhamad, Ahmad Mohd Almulla, Ziyad R Mahfoud

Abstract

Background: Tobacco use is presently responsible for the death of over seven million people across the world. In Qatar, it is one of the main causes of premature deaths and preventable diseases. To reduce tobacco use, Qatar has ratified the World Health Organization (WHO)'s Framework Convention on Tobacco Control (FCTC) and has implemented many tobacco-control initiatives. In spite of these measures, tobacco use is still considered a public health threat in Qatar. Pharmacists practicing in retail/community pharmacy settings are often the first port of call for individuals requiring general health advice. Evidence has proven that they have a pivotal role in health promotion and disease prevention including tobacco cessation. However, pharmacists in Qatar are not actively involved in tobacco control and many have not received any education or training about smoking cessation counseling in the past. In an effort to build the capacity of pharmacists towards tobacco control in Qatar, the aim of the proposed study is to design, implement, and evaluate an intensive education program on tobacco dependence treatment for pharmacists in Qatar.

Methods/design: The study will be a prospective randomized controlled trial comparing an intensive tobacco-related education program versus non-tobacco-related training on pharmacists' tobacco-use-related knowledge, attitudes, self-efficacy, and skills. Community pharmacists practicing in Qatar will be eligible for participation in the study. A random sample of pharmacists will be selected for participation. Consenting participants will be randomly allocated to intervention or control groups. Participants in the intervention group will receive an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco cessation. A short didactic session on a non-tobacco-related topic will be delivered to pharmacists in the control group. The study has two primary outcomes: post-intervention tobacco-related knowledge and post-intervention skills for tobacco cessation assessed using a multiple-choice-based evaluation instrument and an Objective Structured Clinical Examination (OSCE), respectively. The secondary study outcomes are post-intervention attitudes towards tobacco cessation and self-efficacy in tobacco-cessation interventions assessed using a survey instrument. An additional secondary study outcome is the post-intervention performance difference in relation to tobacco-cessation skills in the practice setting assessed using the simulated client approach.

Discussion: If demonstrated to be effective, this education program will be considered as a model that Qatar and the Middle East region can apply to overcome the burden of tobacco-use disorder.

Trial registration: ClinicalTrials.gov, ID: NCT03518476 . Registered on 8 May 2018. Version 1/22 June 2018.

Keywords: Education program; Pharmacist; Qatar; Smoking cessation; Tobacco control.

Conflict of interest statement

Ethics approval and consent to participate

The study protocol and all associated measurement tools, consent forms, and recruitment procedures were reviewed and approved by Qatar University (QU) Institutional Review Board (QU-IRB 906-E/18). The participants will sign written informed consents to participate in this study.

Consent for publication

Not applicable. The manuscript does not report individual data.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
A flow chart of the study methodology and processes
Fig. 2
Fig. 2
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram

References

    1. The World Health Organization: Tobacco. 2018. . Accessed 12 May 2018.
    1. Centers for Disease Control and Prevention: Smoking and Tobacco Use. 2018. . Accessed 12 May 2018.
    1. The World Health Organization: Tobacco Free Initiative fact sheet about health benefits of smoking cessation. 2018. . Accessed 12 May 2018.
    1. Centers for Disease Control and Prevention: Quitting Smoking. 2017. . Accessed 12 May 2018.
    1. U.S. Department of Health and Human Services: Treating tobacco use and dependence: 2008 update. 2008. . Accessed 12 May 2018.
    1. Anderson C, Blenkinsopp A, Armstrong M. The contribution of pharmacy to improving the public’s health. Report 1, Evidence from the peer-reviewed literature. Pharmacy Health Link and Royal Pharmaceutical Society of Great Britain, 2003. ISBN 0-9538505-1-X. . Accessed 12 May 2018.
    1. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med. 2003;25(2):144–153. doi: 10.1093/pubmed/fdg030.
    1. Cipole RJ, Strand LM, Morley PC. Pharmaceutical care practice: The patient-centered approach to medication management. USA: McGraw-Hill Medical, 2012.
    1. Saba M, Diep J, Saini B, Dhippayom T. Meta-analysis of the effectiveness of smoking cessation interventions in community pharmacy. J Clin Pharm Ther. 2014;39:240–247. doi: 10.1111/jcpt.12131.
    1. Afzal Z, Pogge E, Boomershine V. Evaluation of a pharmacist and nurse practitioner smoking cessation program. J Pharm Pract. 2017;30(4):406–411. doi: 10.1177/0897190016659221.
    1. Augustine JM, Taylor AM, Pelger M, Schiefer D, Warholak TL. Smoking quit rates among patients receiving pharmacist-provided pharmacotherapy and telephonic smoking cessation counseling. J Am Pharm Assoc (2003) 2016;56(2):129–136. doi: 10.1016/j.japh.2016.02.001.
    1. Chen T, Kazerooni R, Vannort EM, Nguyen K, Nguyen S, Harris J, et al. Comparison of an intensive pharmacist-managed telephone clinic with standard of care for tobacco cessation in a veteran population. Health Promot Pract. 2014;15(4):512–520. doi: 10.1177/1524839913509816.
    1. El Hajj MS, Kheir N, Al Mulla AM, Shami R, Fanous N, Mahfoud ZR. Effectiveness of a pharmacist-delivered smoking cessation program in the State of Qatar: a randomized controlled trial. BMC Public Health. 2017;17(1):215. doi: 10.1186/s12889-017-4103-4..
    1. Gong J, Baker CL, Zou KH, Bruno M, Jumadilova Z, Lawrence D, et al. A pragmatic randomized trial comparing telephone-based enhanced pharmacy care and usual care to support smoking cessation. J Manag Care Spec Pharm. 2016;22(12):1417–1425.
    1. Shen X, Bachyrycz A, Anderson JR, Tinker D, Raisch DW. Improving the effectiveness of pharmacist-assisted tobacco cessation: a study of participant- and pharmacy-specific differences in quit rates. Ann Pharmacother. 2015;49(3):303–310. doi: 10.1177/1060028014563949.
    1. The International Pharmaceutical Federation. FIP Statement of Policy: the Role of the Pharmacist in Promoting a Tobacco Free Future. 2003. . Accessed 12 May 2018.
    1. Hudmon KS, Corelli RL. ASHP therapeutic position statement on the cessation of tobacco use. Am J Health Syst Pharm. 2009;66:291–307. doi: 10.2146/ajhp070303.
    1. Adult Tobacco Survey Qatar. 2013. . Accessed 12 May 2018.
    1. The World Health Organization: Global Youth Tobacco Survey Qatar. 2014. . Accessed 12 May 2018.
    1. Qatar Ministry of Public Health: Current Status and Objectives: Cardiovascular Diseases. 2018. . Accessed 12 May 2018.
    1. Qatar Cancer Country Profile 2014. . Accessed 12 May 2018.
    1. Smoking—Addressing a National Epidemic. .Accessed 12 May 2018.
    1. Law No. 10 of 2016 on the Control of Tobacco and its Derivatives. . Accessed 12 May 2018.
    1. Qatar Ministry of Public Health: Current Status and Objectives: Tobacco cessation. . Accessed 12 May 2018.
    1. Qatar Council for Healthcare Practitioners: . Accessed 9 June 2018.
    1. El Hajj MS, Al Nakeeb RR, Al-Qudah RA. Smoking cessation counseling in Qatar: community pharmacists’ attitudes, role perceptions and practices. Int J Clin Pharm. 2012;34:667–676. doi: 10.1007/s11096-012-9663-x.
    1. Ye L, Goldie C, Sharma T, John S, Bamford M, Smith PM, Selby P, Schultz ASH. Tobacco-nicotine education and training for health-care professional students and practitioners: a systematic review. Nicotine Tob Res. 2018;20(5):531–542. doi: 10.1093/ntr/ntx072.
    1. Association for the Treatment of Tobacco use and Dependence: Core Competencies For Evidence-based Treatment of Tobacco Dependence. 2005. . Accessed 12 May 2018.
    1. Xu T, de Almeida Neto AC, Moles RJ. A systematic review of simulated patient methods used in community pharmacy to assess the provision of non-prescription medicines. Int J Pharm Pract. 2012;20:307–319. doi: 10.1111/j.2042-7174.2012.00201.x.
    1. Mesquita AR, de Oliveira Sa DA, Santos AP, de Almeida Neto A, Lyra DP., Jr Assessment of pharmacist’s recommendation of non-prescription medicines in Brazil: a simulated patient study. Int J Clin Pharm. 2013;35(4):647–655. doi: 10.1007/s11096-013-9787-7.
    1. Saba M, Diep J, Bittoun R, Saini B. Provision of smoking cessation services in Australian community pharmacies: a simulated patient study. Int J Clin Pharm. 2014;36:604–614. doi: 10.1007/s11096-014-9944-7.
    1. Chiang PP, Chapman S. Do pharmacy staff recommend evidenced-based smoking cessation products? A pseudo patron study. J Clin Pharm Ther. 2006;31(3):205–209. doi: 10.1111/j.1365-2710.2006.00649.x.
    1. Qatar Ministry of Public Health: Clinical guidelines for the State of Qatar. Management of tobacco dependency. 2016. . Accessed 12 May 2018.
    1. Schulz KF, Altman DG, Moher D, for the CONSORT Group CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. BMJ. 2010;340:c332. doi: 10.1136/bmj.c332.
    1. Greenhalgh T, Macfarlane F, Steed L, Walton R. What works for whom in pharmacist-led smoking cessation support: realist review. BMC Med. 2016;14:209. doi: 10.1186/s12916-016-0749-5.
    1. The World Health Organization Europe: WHO European Strategy for Smoking Cessation Policy. 2004. . Accessed 12 May 2018.

Source: PubMed

3
Prenumerera